SciClone Pharmaceuticals (Holdings) Limited
SciClone Pharmaceuticals (Holdings) Limited, headquartered in China, is a prominent player in the biopharmaceutical industry, specialising in the development and commercialisation of innovative therapies. Founded in 1995, the company has made significant strides in addressing unmet medical needs, particularly in oncology and infectious diseases. With a strong operational presence in Asia and expanding into global markets, SciClone is renowned for its flagship product, ZADAXIN, a thymosin alpha 1 therapy that enhances immune response. This unique offering positions the company as a leader in immunotherapy, catering to both patients and healthcare providers. SciClone's commitment to research and development, coupled with strategic partnerships, has solidified its market position, making it a key contributor to the advancement of biopharmaceutical solutions. The company continues to focus on delivering high-quality, effective treatments that improve patient outcomes worldwide.
DitchCarbon Score
How does SciClone Pharmaceuticals (Holdings) Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
SciClone Pharmaceuticals (Holdings) Limited's score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
SciClone Pharmaceuticals (Holdings) Limited's reported carbon emissions
In 2022, SciClone Pharmaceuticals (Holdings) Limited reported total carbon emissions of approximately 90,100 kg CO2e, all of which were classified under Scope 2 emissions. This represents a significant decrease from 2021, when the company recorded total emissions of about 111,180 kg CO2e, also entirely from Scope 2. In 2020, the emissions were notably higher at approximately 292,800 kg CO2e, indicating a positive trend in reducing their carbon footprint over the past two years. Despite these reductions, SciClone Pharmaceuticals has not set any specific reduction targets or initiatives, nor do they participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The company has not disclosed any Scope 1 or Scope 3 emissions data, which limits the comprehensiveness of their climate impact assessment. Overall, while SciClone Pharmaceuticals has made strides in reducing their Scope 2 emissions, the absence of formal reduction commitments or targets suggests there is room for further improvement in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | - | - | - |
| Scope 2 | 292,800 | 000,000 | 00,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
SciClone Pharmaceuticals (Holdings) Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
